Key Highlights

  • Island Pharmaceuticals (ASX:ILA) shares were down 10.29% at $0.305 during the 22 October 2026 trading session.
  • In its 19 October 2026 announcement, the company said 22 non-human primates had completed screening for a planned 20-animal Galidesivir study.
  • Dosing is anticipated to commence in the fourth quarter of calendar 2026, with observations expected to run about 30 days.

Island Pharmaceuticals Ltd (ASX:ILA) shares were down 10.29% at $0.305 during the trading session on 22 October 2026, at the time of the data. During the trading session on 22 October 2026, the S&P/ASX 200 stood at 8,792.20, down 0.44%, while the All Ordinaries stood at 8,916.20, down 0.45%. Island is a Melbourne-based antiviral drug development and biodefence company focused on urgent viral diseases and public health or biosecurity threats. In an ASX announcement dated 19 October 2026, the company reported that 22 non-human primates had completed screening and preparation ahead of a planned Galidesivir dose optimisation study at the United States Army Medical Research Institute of Infectious Diseases.

About the Company

Island Pharmaceuticals is listed on the Australian Securities Exchange under the ticker ILA. Its registered office is in Hawthorn East, Victoria, and the announcement was issued from Melbourne. The company describes its focus as areas of unmet need in urgent viral diseases and biosecurity threats.

Business Overview

Island is executing a dual development strategy built around two assets, ISLA-101 and Galidesivir. ISLA-101 is described as having a well-established safety profile and is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne diseases.

Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity across more than 20 RNA viruses, including Ebola, Marburg, MERS, Zika and yellow fever. The company states that its Galidesivir program builds on more than US$70 million of prior US Government investment and an established body of preclinical and clinical safety and efficacy data.

Animal Screening and Preparation Completed

In its announcement dated 19 October 2026, Island said all 22 non-human primates had passed health and suitability assessments and completed specialised training. Twenty animals are required for the study, and the remaining two are available as reserves.

The training included progressive acclimatisation to jackets and tethering equipment, which will be used when treatment is administered and blood samples are collected in series. The company said this supports reliable collection of pharmacokinetic and other data. Dosing is anticipated to commence during the current quarter, the fourth quarter of calendar 2026.

Design of the USAMRIID Study

The 20-animal study will be conducted within USAMRIID's Biosafety Level 4 facilities under Island's Cooperative Research and Development Agreement with USAMRIID and The Geneva Foundation. It will evaluate Galidesivir against the Angola strain of Marburg virus, with treatment initiated either 24 or 48 hours after exposure.

Varying dose regimens will be given intravenously over a 14-day treatment period. The primary endpoint is survival at 28 days post-exposure, supported by assessments of viral load, clinical signs and pharmacokinetics. Observations are expected to conclude roughly 30 days after commencement, with topline results to follow completion of the study and analysis of the data.

Wider Galidesivir Program and Regulatory Pathway

Island described the study as a component of its development pathway for Galidesivir under the US Food and Drug Administration's Animal Rule, which provides a potential regulatory approval pathway where human efficacy trials are not ethical or feasible. Data from the study will inform dose selection and design of a planned pivotal study.

The company is also progressing a 12-animal study at Texas Biomedical Research Institute, evaluating treatment started after the onset of clinical disease. Previously generated data showed approximately 94% survival in Galidesivir-treated animals infected with the Marburg Musoke strain, compared with no survival in placebo-treated controls.

Related Sector Context

Antiviral and biodefence development covers medicines aimed at infectious diseases and biosecurity threats, often progressing through preclinical animal studies, regulatory consultation and later-stage evaluation. Funding and timelines in this field frequently depend on government programs and specialised facilities. With the S&P/ASX 200 down 0.44% and the All Ordinaries down 0.45%, the wider market also traded lower during the session.

Risks to Weigh In

The announcement points to several uncertainties. Dosing has not yet started, and its timing is described as anticipated for the current quarter. Study outcomes are unknown until observations conclude and the data is analysed.

The regulatory route under the Animal Rule is described as potential rather than assured. The program also relies on specialised third-party facilities, including a Biosafety Level 4 laboratory, and on a Texas Biomedical study that remains in progress.

Catalysts on Watch

Milestones stated in the announcement include the start of dosing in the fourth quarter of calendar 2026, the roughly 30-day observation period that follows, and topline results after analysis. The Texas Biomedical study, the design of the planned pivotal confirmatory efficacy study are also referenced.

Putting It Together

Island Pharmaceuticals traded lower during the 22 October 2026 session, at $0.305, while its latest announcement is dated 19 October 2026. That update confirmed that animal screening for the USAMRIID Marburg study is complete, with dosing anticipated this quarter and topline results to follow the observation period and data analysis.